secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001213900-25-020366
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Q4 net loss $12.8M, cash $170M; ADVANCED-2 12-month data by mid-2025
----------------------------------------------------------------------------

- Cash and equivalents $170.3M as of Dec 31, 2024, funded into 2027 after $100M public offering.
- Full year 2024 net loss $44.6M ($2.17/share) vs $40.4M ($3.57/share) in 2023.
- ADVANCED-2 trial: 12-month data from evaluable NMIBC patients expected by mid-2025; 72% CR at 6 months reported.
- THRIVE-3 registrational trial of IV Choline Chloride to start in 1H 2025; FDA Fast Track granted.
- STARBORN-1 interim update for TARA-002 in pediatric LMs expected by end of 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/0001213900-25-020366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea0232641-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-020366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer